Plectasin is an antibiotic found by Novozymes in the Pezizalean fungus Pseudoplectania nigrella. Plectasin belongs to the antimicrobial peptide class called Defensins, which is also present in invertebrates such as flies and mussels. Pre-clinical tests in mice have shown promising results in that multiresistant bacteria have problems mutating resistance against plectasin, which acts by directly binding the bacterial cell-wall precursor Lipid II. At the end of 2008, Novozymes signed a global licensing agreement with Sanofi-Aventis for the further development and marketing of NZ2114, a derivative of plectasin, as a treatment for gram-positive bacterial infections, e.g. Streptococcus and Staphylococcus which are resistant to all existing antibiotics.
- "Novozymes reveals knowledge on new antibiotic against resistant bacteria". Novozymes. 2010-05-28. Retrieved 2010-05-28.
- "Plectasin NZ2114 - Novel Microbial Agent". Drug Development Technology. Retrieved 2010-05-28.
- Kristensen, HH et al (2010). "Plectasin, a Fungal Defensin, Targets the Bacterial Cell Wall Precursor Lipid II". Science 328 (5982): 1168–1172. doi:10.1126/science.1185723.
- Kristensen, HH et al (2009). "In Vivo Pharmacodynamic Characterization of a Novel Plectasin Antibiotic, NZ2114, in a Murine Infection Model". Antimicrob Agents Chemother. 53 (7): 3003–3009. doi:10.1128/AAC.01584-08. PMC 2704636. PMID 19414576.
|This systemic antibacterial-related article is a stub. You can help Wikipedia by expanding it.|